OTCQB: PHRRF | CSE: PHRM
PharmaTher (OTCQB: PHRRF) (CSE: PHRM)
  • HOME
    • TEAM
  • PORTFOLIO
    • PERSONALIZ3D™
    • KetaMist®
    • Psychedelics
    • Investments
  • INVESTORS
  • NEWS
  • HOME
    • TEAM
  • PORTFOLIO
    • PERSONALIZ3D™
    • KetaMist®
    • Psychedelics
    • Investments
  • INVESTORS
  • NEWS

Press Releases

2/21/2024

PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of  Patented Reformulated Cepharanthine for Phase 1 Study in Australia

 

Read More

2/12/2024

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

 

Read More

    Archives

    July 2026
    May 2026
    April 2026
    March 2026
    February 2026
    January 2026
    December 2025
    November 2025
    October 2025
    August 2025
    July 2025
    June 2025
    May 2025
    March 2025
    February 2025
    January 2025
    November 2024
    October 2024
    September 2024
    August 2024
    May 2024
    April 2024
    February 2024
    January 2024
    September 2023
    July 2023
    June 2023
    May 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020

Psychedelic Pharmaceuticals
PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario, M5C 1P1
​Canada
​Tel: 1-888-846-3171
Email Us
© COPYRIGHT 2026.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.
"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."